U.S. Vasopressin Market
Vasopressin is secreted by the pituitary gland naturally, and it is an antidiuretic hormone. This hormone acts on blood vessels and kidneys. Vasopressin can be used for treating abdominal roentgenography, diabetes insipidus, abdominal distention and gastrointestinal bleeding. It is easily available in the form of an injection in the United States of America.
Impact of COVID-19:
Due to lockdown globally and disturbances in the transportation system, the supply chain of vasopressin has been disturbed in the U.S. during the pandemic. Traveling constraints, social distancing measures and quarantines have led to a reduction in the business of the U.S. vasopressin market.
However, key players in the market are focusing on new initiatives for increasing the availability of vasopressin in treating of several diseases, and it is anticipated to fuel the growth of the U.S. vasopressin market during the forecast period. For instance, in April 2020, Cumberland Pharmaceuticals Inc declared their new initiative for increasing the availability of Vaprisol injection required for treating hyponatremia, and this treatment has been approved by the U.S. FDA.
The U.S. vasopressin market is expected to be valued at US$ 894.6 million in 2021, and is estimated to exhibit a CAGR of 14.7% during the forecast period.
Acquire Free Sample Report + All Related Tables & Graphs Study Now @ https://www.coherentmarketinsights.com/insight/request-sample/4985
Rise in the number of regulatory approvals of vasopressin is estimated to boost the growth of U.S. vasopressin market during the forecast period. For instance, Eagle Pharmaceuticals declared that they have received approval from the U.S. FDA for their abbreviated new drug application ‘ANDA’ for vasopressin in December 2021.
Moreover, increasing prevalence of health conditions and chronic diseases such as cardiovascular diseases, diabetes insipidus, septic shock and many others which can be treated using vasopressin is anticipated to fuel the growth of the U.S. vasopressin market over the forecast period. For instance, in February 2019the JAMA Network Open journal published an article depending on the data collected from January 1, 2017 to March 31, 2018, mentioning that 52.8% of hospitalized patients in the U.S. were suffering from sepsis and it was the main cause of death for 34.9% hospitalized patients. The study also concluded that sepsis led to the death of around 250,000 individuals each year, affecting almost 1.7 million people in the United States of America.
Complications like asthma, cardiac arrest and others developed during the use of vasopressin are anticipated to hamper the growth of the U.S. vasopressin market during the forecast period. For instance, in October 2018, the Journal of International Medical Research published an article stating the various complication that can occur due to administration of high concentration of vasopressin in a patient. Myocardial ischemia, gastrointestinal ischemia bradycardia and a few other complications can occur, severe cases can also lead to cardiac arrest.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4985
- Intravenous Injection
- Intramuscular Injection
- Subcutaneous Injection
- Anti-diuretic Hormone Deficiency
- Gastrointestinal Bleeding
- Vasodilatory Shock
- Ventricular Tachycardia
By End User:
- Dental Clinics
Key players active in the U.S. vasopressin market are Azevan Pharmaceuticals, Inc, Par Pharmaceutical, Otsuka Holdings Co., Ltd, Par Pharmaceutical, Athenex, Inc., Pfizer Inc, Dr. Reddy’s Laboratories Ltd., Eagle Pharmaceuticals, Inc, Cumberland Pharmaceuticals Inc. and Astellas Pharma Inc.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4985
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 U.S. Vasopressin Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: U.S. Vasopressin Market Industry Impact
Chapter 2 U.S. Vasopressin Market Competition by Types, Applications, and Top Regions and Countries
2.1 U.S. Vasopressin Market (Volume and Value) by Type
2.3 U.S. Vasopressin Market (Volume and Value) by Regions
Chapter 3 U.S. Vasopressin Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 U.S. Vasopressin Market Landscape
4.1 Market Overview
4.3 Application/End Users
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Automotive Adaptive Front Lighting Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest U.S. Vasopressin Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Trading Analysis
8.1 Export of Automotive Adaptive Front Lighting by Region
8.2 Import of Automotive Adaptive Front Lighting by Region
8.3 Balance of Trade
Chapter 9 Historical and Current U.S. Vasopressin in North America (2016-2021)
9.1 U.S. Vasopressin Supply
9.2 U.S. Vasopressin Demand by End Use
9.3 Competition by Players/Suppliers
9.4 Type Segmentation and Price
9.5 Key Countries Analysis
Chapter 10 Company Profiles and Key Figures in U.S. Vasopressin Market Business
Chapter 11 U.S. Vasopressin Market Forecast (2021-2028)
Chapter 12 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027